Commentary
Diarrhea kills nearly 650 children below the age of 5 years each day in India. Oral rehydration solution (ORS) and oral zinc have been recommended for the treatment of acute diarrhea in children by the Indian Academy of Paediatrics (IAP) National task force for use of ORS and zinc in the year 2003 [1] and later endorsed in 2006. [2] Zinc was included in the National Programme for the treatment of Diarrhea in 2007. [3] The Integrated Management of Neonatal and Childhood Illness (IMNCI) advocates the use of these two drugs in the treatment of acute diarrhea. [4] The evidence for the use of ORS and zinc as fi rst-line treatment in children in resource limited countries is overwhelming. [5, 6] If given early on during an episode of diarrhea it would help save 50% of children who would otherwise die. The treatment is effective, safe, cheap, and easily tolerated by children. [6] More importantly, there are no other alternatives to this treatment. Recognizing the importance of this, the National Rural Health Mission (NRHM) has included ORS and zinc in the list of medicines to be available at the subcenters. [3] Yet, unfortunately, it is hardly available in the public [7] [8] [9] and private [7, 8] health facilities in India. Only 34.2% of children with diarrhea in India receive ORS [10] and a miniscule 1% are prescribed zinc during an episode of diarrhea. [11] The lack of availability in public health facilities [7] [8] [9] points to the fact that zinc was probably not procured at all, or if procured it was not done in suffi cient quantities. Why does this state of affairs persist? We explore some of the regulatory and other issues which prevent access to zinc in India.
REGULATORY ISSUES
It is evident that in order to promote wide use of zinc and ORS these should be available as over the counter (OTC) drugs. The consequence of having it as OTC is that people will be able to buy these two medicines at any shop and not only from licensed chemists. Importantly, there are rules and regulations for that specifi c category. For example, the packaging is defi ned; OTC drugs have to be sold in the original packaging so that the consumer can easily identify the drug. Promotion is defi ned; they can usually be advertised in the general media but for specifi c conditions (e.g. headache, fever) and not for specifi c diseases. The generic name must appear in any advertisement. The sales channel is defi ned; in most countries they can be sold in general stores along with other consumer goods. The seller is simply a seller of goods and does not provide information on the OTC product. That is done through promotion in the media and the information on the package. This means that OTC as a specifi c group will have a clear and level "playing fi eld"; which will obviously attract players, in this case the pharmaceutical manufacturers.
In India, the term OTC has no legal recognition. All drugs which are not "prescription-only" are by default considered OTC. Even the so-called OTC drugs like paracetamol (which come under schedule K) have to be sold by licensed drug stores. [12] Non-drug-licensed stores or shops can sell drugs which are under schedule K of the Drugs Control Rules (1945) which are known as "household remedies." [12] These medicines can be sold without a license in villages with a population less than 1000 subject to some other conditions. This rather arbitrary and confusing rule is the fi rst barrier to widespread availability of zinc. Nearly 700 million people in India live in rural areas, away from easy access to health facilities. It is in the interests of these people, the consumers, to have a legally recognized schedule such as OTC to promote access to medicines like ORS and zinc. Countries of the South East-Asia region, such as Thailand, have licensed zinc and ORS as OTC products. ORS is an OTC product in Sri Lanka. At this juncture we should remind ourselves that we are not speaking of a medicine which brings down fever by a few degrees or provides symptomatic relief for trivial conditions like cold and cough or a balm to soothe an itchy skin. We are speaking of simple remedies which have proven effi cacy and safety and will potentially save more than 200,000 children dying each year. It is hard to believe, that despite the many meetings, task force reports, and hard core data to support a prescription to OTC switch, the government has not done so. The time is right for the government to seize the opportunity to defi ne an OTC category and to have zinc and ORS as the fi rst products.
THE "OFFICIAL" STATUS OF ZINC
Tablet zinc sulfate (or any other salt) either in dispersible form or otherwise did not fi nd a place in the National Essential Drugs List 2003. [13] Only zinc oxide (as dusting powder) is mentioned. Even the Standard Treatment Guidelines (STG), brought out by the Armed Forces Medical College, Pune, in collaboration with Ministry of Health and Family Welfare, Govt. of India near the end of 2007, does not list zinc for treatment of diarrhea. [14] The Indian Pharmacopoeia (I.P.) 2007 and 2010 do not give standards for oral tablets (dispersible or otherwise) of zinc sulfate. [15, 16] The recently released National Formulary of India (NFI) 2010 (preprint version) also fails to mention oral zinc [17] though hopefully it may be corrected in the revised version. However, the National List of Essential Medicines India (NLEMI) 2011 lists zinc sulfate syrup (20 mg/5 ml) for diarrhea. [18] A high-level meeting to discuss the role of zinc in diarrhea was held on 20 March 2007 during which the government approved the use of 20 mg dispersible zinc tablets for use in acute diarrhea in children. [19] Despite this "offi cial" status of zinc, none of the publications which have been dated after this meeting such as the STG, I.P., and NFI mention zinc for the management of diarrhea. The NLEMI, released in June 2011, lists only syrup zinc and not dispersible tablets. Such documents of public health importance should be subject to wider participation and greater scrutiny. Medicines in the national programs should be listed in the same formulation after consultation with these programs to avert a disconnect between the NLEMI and national programs. However, individual states like Chhattisgarh, Orissa, Tamil Nadu, and others have included dispersible zinc tablets in their recent essential drug lists, making a small but signifi cant move in the right direction.
What makes the situation more confusing is the statement by the then Drugs Controller General of India (DCGI) at the March 2007 meeting that "zinc is already a non prescription drug and rules permit it for its use as an OTC drug." [19] It
MANUFACTURING CAPACITY FOR ZINC IN INDIA
In April 2008, the Union Minister for Science and Technology, Mr. Kapil Sibal, announced that Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), a public sector undertaking of the Dept. of Biotechnology, Govt. of India, has been equipped with a production capacity of 240 million tablets of BIBZinC (20 mg dispersible scored tablets of zinc sulfate) per year. [20] There have been efforts by the United States Agency for International Development (USAID) to improve the manufacture of zinc with aid up to 1,50,000 U.S. dollars as start-up funds. [21] Companies such as Zuventus (Zinconia), Dr. Reddy's (Z and D), Wallace (ZN), USV (Trustim), Emcure (Emzinc) have started production of oral zinc with some companies exporting the drug. The production capacity for zinc seems adequate to meet the demands of the country.
AVAILABILITY AND COST OF ZINC AND ORS
The ground reality, however, is quite different from what one would expect in a country with a sophisticated pharmaceutical industry. These drug companies (manufacturing zinc) do not come forward to quote in tenders for hospitals (personal experience from JIPMER, Pondicherry) and their products are not easily available in all states of India [ Table 1 ]. The [7] and Orissa [8] Drug names and strength of formulation There certainly is a market for zinc tablets though it would be a high-volume low-margin product rather than the low-volume high-margin one like the "morning after" pill. The opportunity for pharmaceutical companies to be associated in the public mind (through advertising to the general public) with a proven useful product is not one they would miss.
One hundred tablets of zinc sulfate are priced at Indian rupees (INR) 13.68 to be supplied to the Tamil Nadu Government for the current year. [22] Therefore, a 2-week course of zinc for a child will cost the Tamil Nadu Government less than two rupees. A single sachet of ORS (20.5 g) costs INR 1.58 to the Tamil Nadu Medical Services Corporation. [22] The cost of ORS and zinc for pooled procurement by the government is clearly well within the medicines budget for nearly all states. Why are public health facilities still not able to stock these medicines in suffi cient quantities? Poor supply chain management, lack of prescribers prescribing them in diarrhea, and inadequate procurement at the central drug store all contribute.
In the private chemist shops of Tamil Nadu, a single sachet of ORS costs between INR 12-15 and a course of zinc sulfate tablets costs 30-40 rupees. This puts zinc and ORS out of the reach for those who go to public health facilities for treatment because they cannot afford private care. The National Pharmaceutical Pricing Authority should discuss the price of zinc tablets and ORS with the manufacturers. An adequate return to the manufacturer should be assured, but the public health importance should be the primary concern.
Pricing and availability surveys in Orissa and Chhattisgarh have shown that though the availability of ORS is relatively good it is pretty dismal for zinc [ Table 1 ]. This was also refl ected in a snap-shot survey of fi ve essential pediatric medicines undertaken previously. [9] It is highly anomalous that the vastly developed pharmaceutical industry in India is unable to make available a simple product which is needed for millions of its population on a regular basis. Indian pharmaceutical companies have been praised extensively for their role in responding to patients with HIV-AIDs by making good quality, affordable antiretrovirals available globally. Surely these same companies should be able to relate to the needs of the children in India?
WHAT NEEDS TO BE DONE?
The Ishikawa's Fishbone diagram [ Figure 1 ] illustrates the possible causes of poor availability of zinc and demonstrates the interwoven elements that facilitate and hinder the rational use of zinc. Perhaps the fi rst thing the government needs to do is make sure that all the "offi cial" documents, like NLEMI 2011, STG, I.P 2010, and NFI 2010, list oral zinc for diarrhea and are in alignment with each other regarding the formulation and strength. Departments within the government must consult and collaborate with each other and produce documents that are in alignment. Next, there is an urgent need to formally make zinc sulfate and ORS available widely, through distribution channels outside the pharmacies and medicines shops. As mentioned before this would provide the DCGI an opportunity defi ne the "OTC" segment; it can be done through promulgation of regulations and does not require parliamentary action. This will ensure that these drugs can be sold in all shops (without a license), promoted by direct to consumer marketing and people will have easy access to them. These products should be advertised, ethically, using effective promotional measures targeting all sections of society.
Simultaneously, there has to be an advocacy campaign by the Ministry of Health to urge prescribers to comply with the STGs for diarrhea. A recent survey in Ujjain shows the pathetic concordance to STGs in acute diarrhea with only 6 out of the 843 prescriptions being compliant. [23] A media blitz of the kind which was used to promote ORS in the early 1990s should be planned to promote ORS and zinc to mothers and care-givers of children. Efforts should be made to convince care-givers to continue with zinc even after the episode of diarrhea is over and to caution them regarding palatability issues. Using FM radio stations, local cable networks, text messages on mobile phones, newspaper and other modalities, a concentrated effort to educate the public should be made. Companies manufacturing zinc should be permitted to ethically promote their products to the public. Irrational indications on promotional material [24] should be scanned and weeded out or else the wheat will get buried with the chaff [see Figure 2 ].
Pharmaceutical companies manufacturing zinc should be assured of regular orders from public and private health care facilities. This will happen only if the procurement lists of all states and major hospitals have zinc in them in adequate quantities. This by itself may not be suffi cient for pharmaceutical companies to start producing more zinc, but could be a small motivator which may slowly turn the tide. But the writing on the wall is clear -the drug regulatory authority and the ministry of health must clarify the situation; the DCGI could have the "OTC" classifi cation of ORS and zinc as an agenda item in his next meeting with the State Drug Controllers. Such a commitment to this issue will prevent the needless deaths of children. Zinc, ORS, and deaths in childhood diarrhea is a solution waiting to happen; each day the solution is delayed is one day too much for the children of India. 
